NR AXWM
AU Skinningsrud,A.; Gundersen,A.; Stenset,V.; Johnsen,L.; Fladby,T.
TI Tau Protein and Hyperphosphorylated Tau Protein in CSF for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease
QU International Conference - Prion 2007 (26.-28.9.2007) Edinburgh International Conference Centre, Edinburgh, Scotland, UK - Book of Abstracts: Pathology and Pathogenesis P03.56
IA http://www.prion2007.com/pdf/Prion Book of Abstracts.pdf
PT Konferenz-Poster
AB
Sporadic Creutzfeldt-Jakob disease (CJD) has an incidence of approximately 1/mill/year in Europe and is the only form of CJD that has been described in Norway. Due to few specific pre-mortal diagnostic signs, it is difficult to separate CJD from rapidly developing Alzheimer's disease (AD) and other rapidly developing neurological diseases. The total concentration of tau protein (tTau) in CSF has previously been found to separate patients with CJD completely from those with AD. An increased concentration of tTau is regarded to be an unspecific marker for degradation of neurons. The success of tTau as a marker for CJD depends on whether other neurological diseases have the same high rate of neuronal decay. As 181hyperphosphorylated tau (P-Tau) is more specific for AD, one would expect the diagnostic specificity for CJD to rise by combining the two markers. The ratio of tTau/P-Tau has been described to separate CJD from other neurodegenerative diseases without overlap.
We compared the performance of tTau alone and tTau/P-Tau-ratio for the diagnosis of CJD.
CSF for routine analyses of the biological markers tTau and P-Tau were sent to our laboratory from several neurological departments in Norway from August 2005 to May 2007. All patients with tTau values >1200 ng/L (ordinarily used reference limit 450 ng/L) were selected; approximately 30 patients; this included all patients with definite and probable CJD.
Choosing cut-off values for tTau and tTau/P-Tau with 100% sensitivity for CJD, gave a higher specificity for tTau/P-Tau than for tTau alone. The predictive value of a positive test for tTau/P-Tau was also slightly higher than for tTau. The remaining (non-CJD) patients had AD or AD combined with vascular dementia (AD/VD), and a few patients had other rapidly progressing neurological diseases. As expected, tTau/P-Tau separated CJD better from AD, AD/VD than tTau. t-Tau and tTau/P-Tau are useful but non-specific markers for CJD.
AD A. Skinningsrud, A. Gundersen, V. Stenset, L. Johnsen, T. Fladby, Akershus University Hospital, Norway
SP englisch
PO Schottland